Zobrazeno 1 - 10
of 369
pro vyhledávání: '"Programmed cell death protein 1 (PD-1)"'
Autor:
Jian Zhang, Aiqin Gao, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Yuping Sun
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Patients receiving PD-(L)1 inhibitors frequently encounter unusual side effects known as immune-related adverse events (irAEs). However, the correlation of irAEs development with clinical response in small cell lung cancer (SCLC)
Externí odkaz:
https://doaj.org/article/81edf98278c9466d9563b891d6a4d6fb
Autor:
Zhitao Dong, Chengjun Sui, Jiongjiong Lu, Junwu Guo, Kecai Duan, Kui Wang, Li Geng, Binghua Dai, Jiamei Yang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundCurrently, the prognosis of advanced intrahepatic cholangiocarcinoma (ICC) is poor, and the current treatment methods are not effective.ObjectiveThe aim of this study was to evaluate the anticancer efficacy of chemotherapy combined with PD-
Externí odkaz:
https://doaj.org/article/08d8de606c4b4a05af116d358e57739d
Publikováno v:
Biomolecules & Biomedicine (2024)
The application of immune checkpoint inhibitors has proven to be an effective treatment for cancer. Immune checkpoints such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated pr
Externí odkaz:
https://doaj.org/article/07da0ce7416b417baaa5e1cbbf0deb18
Autor:
Anna Qin, Yuan Qin, Joseph Lee, Anna Musket, Mingyao Ying, Giedre Krenciute, Francesco M. Marincola, Zhi Q. Yao, Phillip R. Musich, Qian Xie
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Recent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors including hepatocellular carcinoma (HCC). Overexpression of MET receptor tyrosine kinase is common
Externí odkaz:
https://doaj.org/article/c7814fd1c0f24ba28819f129766ab27f
Autor:
Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4265-4272 (2022)
Abstract Background Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non‐small cell lun
Externí odkaz:
https://doaj.org/article/1f64b72ea62f4d40a0b47d3d61bc865c
Publikováno v:
Cancer Communications, Vol 42, Iss 10, Pp 937-970 (2022)
Abstract In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small
Externí odkaz:
https://doaj.org/article/266b158a350a4c07bb03c7b763be4290
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Various immunotherapies have demonstrated remarkable success over the past few decades, and have been approved for the treatment of different cancer types. However, patient responses to immunotherapy are variable, and approximately 50% of cases are r
Externí odkaz:
https://doaj.org/article/9ba2f40de8854f639dcab0ce08a8a957
Autor:
Fadhl Alshaebi, Mohammed Safi, Yousif A. Algabri, Mahmoud Al-Azab, Abdullah Aldanakh, Mohammed Alradhi, Alariqi Reem, Caiqing Zhang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Interleukin-34 (IL-34) is a cytokine that is involved in the regulation of immune cells, including macrophages, in the tumor microenvironment (TME). Macrophages are a type of immune cell that can be found in large numbers within the TME and have been
Externí odkaz:
https://doaj.org/article/cb4ee40963b54553ad76feccae1d0024
Autor:
Fenna de Vries, Adrianus A. J. Smit, Gertjan Wolbink, Annick de Vries, Floris C. Loeff, Eric J. F. Franssen
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
BackgroundPembrolizumab is a well-tolerated biologic agent with a potentially stable and durable anti-tumor response. Unfortunately, discontinuation of therapy can occur as a consequence of immune-related adverse effects (irAEs). These irAEs appear i
Externí odkaz:
https://doaj.org/article/80f9f5ef5d7443cb95508f45902e8801
Autor:
Kishan R. Bharadwa, Kuheli Dasgupta, Suma Mysore Narayana, C. Ramachandra, Suresh M.C. Babu, Annapoorni Rangarajan, Rekha V. Kumar
Publikováno v:
European Journal of Breast Health, Vol 18, Iss 1, Pp 21-29 (2022)
Objective:The interaction between programmed cell death protein 1 (PD-1) on activated T-lymphocytes and programmed death-ligand 1 (PD-L1) on tumor cells or antigen-presenting cells sends immunosuppressive signals leading to the escape of tumor cells
Externí odkaz:
https://doaj.org/article/b473bada81ba4d62a956b47b6463616a